Feb 24, 2026Senolytics and Cellular Senescence: Mechanisms, Mayo Clinic Evidence, and Clinical StatusSenolytics are drugs and compounds that selectively clear senescent cells, which accumulate with age and drive chronic inflammation. This review covers the mechanisms, the Mayo Clinic dasatinib+quercetin trials, fisetin evidence, and the current clinical status.
Feb 18, 2026Dasatinib and Quercetin for Senolytic Therapy: Mayo Clinic Phase 2 Trial FindingsA Mayo Clinic Phase 2 trial tested dasatinib plus quercetin in 60 older women with low bone density, finding improved bone formation markers. Dasatinib is an FDA-approved cancer drug requiring physician supervision.
Feb 8, 2026Dasatinib + Quercetin Senolytic Protocol: Intermittent Dosing, Safety, and Clinical Trial EvidenceThe dasatinib + quercetin (D+Q) combination is the most clinically studied senolytic protocol. Mayo Clinic trials show clearance of senescent cells and functional improvements. Dasatinib is a chemotherapy drug with significant side effects — this is not a casual intervention.